Home

Loading...

Table of contents

Hairy cell leukemia

Guidelines

Key sources

The following summarized guidelines for the evaluation and management of hairy cell leukemia are prepared by our editorial team based on guidelines from the European Society of Medical Oncology (ESMO 2015) and the British Committee for Standards In Haematology (BCSH 2012). ...
Show more

Classification and risk stratification

Prognosis
As per ESMO 2015 guidelines:
Recognize that the following biological factors are associated with poor outcomes:
presence of TP53 mutations
lack of somatic mutations in the IGVH genes (occur in a minor proportion of patients)
VH4-34 family usage (more frequently seen in HCL variant)
B
Recognize that complete response is associated with a significantly longer disease-free survival than partial response.
B
Create free account

Diagnostic investigations

Peripheral blood smear: as per ESMO 2015 guidelines, obtain peripheral blood smear and peripheral blood flow cytometry in patients with suspected classical HCL.
B

Diagnostic procedures

Bone marrow biopsy
As per ESMO 2015 guidelines:
Obtain flow cytometry in bone marrow aspirate and perform bone marrow trephine biopsy with immunohistochemistry in patients with suspected classical HCL. Perform bone marrow examination for the diagnosis, particularly after treatment, to assess response.
B
Obtain BRAF mutation analysis of exon 15 in difficult cases.
B

Medical management

Indications for treatment, asymptomatic patients: as per ESMO 2015 guidelines, do not initiate treatment in asymptomatic patients.
D
follow-up patients every 3-12 months with complete history, physical examination, CBC, and routine chemistry.
D

More topics in this section

  • Indications for treatment (symptomatic patients)

  • Purine analogs

  • Interferon-alpha

  • Growth factors

Therapeutic procedures

Blood product transfusion: as per BCSH 2012 guidelines, administer only irradiated blood products in patients treated with cladribine or pentostatin and requiring transfusion, in order to minimize the risk of transfusion-associated GvHD.
B

More topics in this section

  • Stem cell transplantation

Surgical interventions

Indications for splenectomy: as per ESMO 2015 guidelines, consider performing splenectomy in patients with resistant massive symptomatic splenomegaly (> 10 cm below the costal margin) with accompanied low-level bone marrow infiltration.
C
Show 3 more

Specific circumstances

Pregnant patients: as per ESMO 2015 guidelines, initiate treatment in pregnant patients with HCL only when truly warranted.
B
Show 3 more

More topics in this section

  • Patients with HCL variant

Preventative measures

Antibiotic prophylaxis: as per ESMO 2015 guidelines, administer prophylactic co-trimoxazole (960 mg 3 times weekly) until the lymphocyte count increases to > 1×10⁹/L for the prevention of pneumocystis infections in patients with lymphopenia treated with nucleoside analogs.
B

More topics in this section

  • Antiviral prophylaxis

Follow-up and surveillance

Assessment of treatment response: as per ESMO 2015 guidelines, perform bone marrow examination for the assessment of response to treatment.
B

More topics in this section

  • Management of relapsed/refractory disease